FMP
H-CYTE, Inc.
HCYT
PNK
Inactive Equity
H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
0.995 USD
-0.005 (-0.503%)
About
ceo
Mr. Michael W. Yurkowsky
sector
Healthcare
industry
Biotechnology
website
https://www.hcyte.com
exchange
PNK
Description
H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
CIK
0001591165
ISIN
US4041241096
CUSIP
404124109
Address
2202 North West Shore Boulevar...
Phone
888 664 2983
Country
US
Employee
2
IPO Date
Dec 19, 2014
Summary
CIK
0001591165
Exchange
PNK
Industry
Biotechnology
Sector
Healthcare
CUSIP
404124109
ISIN
US4041241096
Country
US
Price
0.99
Beta
0.52
Volume Avg.
796
Market Cap
624.98k
Shares
-
52-Week
0.5002-7.0
DCF
5.75
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.06
P/B
-
Website
https://www.hcyte.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest HCYT News
It looks like there's no news available.
